Edition:
United Kingdom

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

12.80USD
14 Dec 2018
Change (% chg)

$-0.60 (-4.48%)
Prev Close
$13.40
Open
$13.15
Day's High
$13.59
Day's Low
$12.61
Volume
150,031
Avg. Vol
148,471
52-wk High
$41.24
52-wk Low
$12.61

Latest Key Developments (Source: Significant Developments)

La Jolla Pharma Co Announces Financial Results For The Three And Nine Months Ended September 30, 2018
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018.LA JOLLA PHARMACEUTICAL CO - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $1.93.LA JOLLA PHARMACEUTICAL CO - AS OF SEPTEMBER 30, 2018, LA JOLLA HAD $204.3 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

La Jolla Pharmaceutical Company Reports Qtrly Loss Per Share Of $2.02
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - La Jolla Pharmaceutical Co ::MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND RECENT CORPORATE PROGRESS.QUARTERLY LOSS PER SHARE $2.02.QUARTERLY TOTAL REVENUE $1.6 MILLION VERSUS NIL REVENUE.  Full Article

Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - La Jolla Pharmaceutical Co ::BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​.  Full Article

La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018
Friday, 29 Dec 2017 

Dec 29 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING.  Full Article

La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - La Jolla Pharmaceutical Co ::U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE.U.S. FDA SAYS GRANTED THE APPROVAL OF GIAPREZA TO LA JOLLA PHARMACEUTICAL COMPANY.U.S. FDA - APPROVES GIAPREZA (ANGIOTENSIN II) INJECTION FOR INTRAVENOUS INFUSION TO INCREASE BLOOD PRESSURE IN ADULTS WITH SEPTIC/OTHER DISTRIBUTIVE SHOCK.  Full Article

La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401
Monday, 18 Dec 2017 

Dec 18 (Reuters) - La Jolla Pharmaceutical Co ::INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC‑401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS.  Full Article

La Jolla Pharma files for mixed shelf of up to $150 mln ‍​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - La Jolla Pharmaceutical Co :Files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

La Jolla reports Q3 loss $1.19/shr
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - La Jolla Pharmaceutical Co :La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Q3 loss per share $1.19.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.La Jolla Pharmaceutical-‍as of Sept 30, 2017, co had $120.8 million in cash,cash equivalents, versus $65.7 million of cash and cash equivalents at Dec 31, 2016​.  Full Article

Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - La Jolla Pharmaceutical Co ::Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍.  Full Article